PetVivo (NASDAQ:PETV), Inc. (NASDAQ: PETV) is a development‐stage medical device company focused on the design, development and commercialization of proprietary platforms for veterinary applications. The company’s core business is centered on the controlled delivery of biologic therapies into the joint space to address osteoarthritis and other musculoskeletal conditions in companion animals and horses. Leveraging its patent‐protected TriVol™ delivery system, PetVivo aims to improve the efficacy and duration of treatment by providing sustained release and targeted distribution of therapeutic compounds directly to the site of injury or inflammation.
The company’s lead product candidate, V-PET™, is an intra‐articular device designed for single‐use administration of biologic agents, such as platelet‐rich plasma (PRP) or stem cells, into canine and equine joints. By combining a flexible delivery scaffold with proprietary hydrogel formulations, V-PET™ seeks to enhance tissue repair and reduce pain in patients suffering from arthritis or joint trauma. PetVivo is also exploring opportunities to extend its platform to support growth factor therapies and other novel biologics under development by third‐party partners.
To advance its commercial objectives, PetVivo has entered into collaborations with veterinary clinics, academic research institutions and contract manufacturing organizations. The company’s go‐to‐market strategy emphasizes strategic alliances for clinical validation, manufacturing scale‐up and distribution across North America. PetVivo continues to engage with regulatory authorities to secure market clearances and is exploring potential expansion into select international markets where demand for advanced veterinary therapies is growing.
Originally founded in 2015 and headquartered in Charleston, South Carolina, PetVivo completed its corporate rebranding after acquiring its core technology and adopting its current name in 2017. The company is led by a management team with extensive experience in medical device development, regulatory affairs and veterinary medicine. PetVivo’s board and executive leadership bring together expertise in biotech innovation, clinical research and commercialization strategies aimed at transforming the standard of care for animal health.
